BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 37844352)

  • 1. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
    Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
    Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
    Metaxa AM; Clarke M
    BMJ; 2024 May; 385():e078084. PubMed ID: 38692686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.
    Rosenblat JD; Leon-Carlyle M; Ali S; Husain MI; McIntyre RS
    Am J Psychiatry; 2023 May; 180(5):395-396. PubMed ID: 36945824
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
    Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
    J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.
    Rosenblat JD; Meshkat S; Doyle Z; Kaczmarek E; Brudner RM; Kratiuk K; Mansur RB; Schulz-Quach C; Sethi R; Abate A; Ali S; Bawks J; Blainey MG; Brietzke E; Cronin V; Danilewitz J; Dhawan S; Di Fonzo A; Di Fonzo M; Drzadzewski P; Dunlop W; Fiszter H; Gomes FA; Grewal S; Leon-Carlyle M; McCallum M; Mofidi N; Offman H; Riva-Cambrin J; Schmidt J; Smolkin M; Quinn JM; Zumrova A; Marlborough M; McIntyre RS
    Med; 2024 Mar; 5(3):190-200.e5. PubMed ID: 38359838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
    Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.
    Agrawal M; Richards W; Beaussant Y; Shnayder S; Ameli R; Roddy K; Stevens N; Richards B; Schor N; Honstein H; Jenkins B; Bates M; Thambi P
    Cancer; 2024 Apr; 130(7):1137-1146. PubMed ID: 38105655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.
    Agin-Liebes G; Davis AK
    Curr Top Behav Neurosci; 2022; 56():125-140. PubMed ID: 34811715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
    Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.
    Prouzeau D; Conejero I; Voyvodic PL; Becamel C; Abbar M; Lopez-Castroman J
    Curr Psychiatry Rep; 2022 Oct; 24(10):573-581. PubMed ID: 35953638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.